ENOV
Enovis Corp Health Care Orthopedic, Prosthetic & Surgical Appliances & Supplies Russell 3000
$19.91Close
$1.1BMarket cap
$17.43 – $31.5152-week range
Nov 5, 2026Next report · before the open
Highlights
Cautions
- Not in an uptrend 0 of 8 trend conditions
- Lagging the market RS 10 · weaker than 90% of stocks over 12 months
- Far from its high 37% below its 52-week high
- Results soon Nov 5, 2026, in 4 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
37%
1wk
down 5.6%
price change
1mo
up 9.0%
price change
12-month return
down 35%
market up 11% ·
its own down 49%
F-score
5 / 9
Mixed
Altman Z
-0.43
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
0.8×
price / book
Earnings yield
down 47.6%
EBIT / enterprise value
Cheaper than
44%
of the market · around average
Revenue growth
up 7%
year on year
EPS growth
—
latest quarter
Sales growth
up 3%
latest quarter · -2 pts
ROE
down 58%
return on equity
Free cash margin
up 1%
$19.9M FCF
D/E
0.85
long-term debt / equity
Net debt / EBITDA
5.6×
Interest cover
Lossoperating loss
Piotroski tests
- not yet profitable on its assets
- profitability slipped from last year
- short-term liquidity weakened
- issued more shares
- generating cash from operations
- profits backed by cash
- reduced long-term debt
- gross margin widened
- assets working harder
Repair signals
- FCF turned positive ($-67M → $20M)
- Gross margin 56.0% → 59.8%
Trade setup
ATR%
5.4%
$1.08 a day · 2×ATR $17.76
RS
10 / 99
vs the universe
Trend
0 / 8
trend template
Relative volume
1.6×
vs 50-day average
Up/down volume
0.88
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 0 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Heavily indebted Net debt is 5.6 times EBITDA — roughly 6 years of earnings before interest, tax and depreciation to repay borrowings in full.
- Shareholders diluted The share count rose 2.4% over the year, from 56m to 57m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Last shock
Sep 1, 2026-17% in one session3.6× volumeon an SEC filing-3% since
Financials
- Gross 60%
- Net -53%
- Free cash 1%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | $1.4B | $1.6B | $1.7B | $2.1B | $2.2B |
| Gross margin | 54% | 55% | 56% | 58% | 56% | 60% |
| Operating income | -$66.2M | -$62.8M | -$71.2M | -$65.7M | -$775.7M | -$1.1B |
| Net income | $42.6M | $71.7M | -$13.3M | -$33.3M | -$825.5M | -$1.2B |
| Net margin | 4% | 5% | -1% | -2% | -39% | -53% |
| Earnings per share | $0.93 | $1.40 | -$0.25 | -$0.61 | -$14.93 | -$20.75 |
| Free cash flow | $187.2M | $251.9M | -$161.3M | $12.8M | -$67.2M | $19.9M |
| Free cash margin | 17% | 18% | -10% | 1% | -3% | 1% |
| Cash | $97.1M | $680.3M | $24.3M | $36.2M | $48.2M | $36.4M |
| Long-term debt | $2.2B | $2.1B | $40.0M | $466.2M | $1.3B | $1.3B |
| Shareholders' equity | $3.5B | $4.6B | $3.4B | $3.4B | $2.6B | $1.5B |
| Shares outstanding | 118.50m | 52.08m | 54.23m | 54.60m | 55.88m | 57.19m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jul 3, 2026 | 34d |
| May 7, 2026 | Quarterly ↗ | Apr 3, 2026 | 34d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 6, 2025 | Quarterly ↗ | Oct 3, 2025 | 34d |
| Aug 7, 2025 | Quarterly ↗ | Jul 4, 2025 | 34d |
| May 8, 2025 | Quarterly ↗ | Apr 4, 2025 | 34d |
| Feb 26, 2025 | Annual ↗ | Dec 31, 2024 | 57d |
| Nov 6, 2024 | Quarterly ↗ | Sep 27, 2024 | 40d |
| Aug 7, 2024 | Quarterly ↗ | Jun 28, 2024 | 40d |
| May 2, 2024 | Quarterly ↗ | Mar 29, 2024 | 34d |
| Feb 22, 2024 | Annual ↗ | Dec 31, 2023 | 53d |
| Nov 7, 2023 | Quarterly ↗ | Sep 29, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 1, 2026 | Regulation FD ↗ |
| Aug 6, 2026 | Results ↗ |
| May 19, 2026 | Director or officer change · Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Feb 26, 2026 | Results ↗ |
| Jan 12, 2026 | Regulation FD ↗ |
| Dec 15, 2025 | Director or officer change ↗ |
| Dec 10, 2025 | Material agreement · New obligation ↗ |
| Nov 14, 2025 | Director or officer change ↗ |
| Nov 6, 2025 | Results ↗ |
| Aug 7, 2025 | Results ↗ |
| May 21, 2025 | Shareholder vote ↗ |